10-KPeriod: FY2000

REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2000

Filed March 2, 2001For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics. As of the period ending December 31, 2000, the company had not yet generated any sales or profits from product commercialization. Its strategy centers on leveraging its proprietary technology platforms to build a diverse pipeline of drug candidates targeting serious medical conditions such as obesity, rheumatoid arthritis, cancer, and asthma. Regeneron aims to retain significant ownership and commercialization rights for its key pipeline assets. The company reported a net loss of $23.2 million for the year ended December 31, 2000, a slight increase from the previous year's net loss of $23.1 million. Total revenues for 2000 grew to $59.3 million, up from $34.5 million in 1999, driven by increased contract research and development, and contract manufacturing revenues, particularly from collaborations with Procter & Gamble and Merck. Research and development expenses also rose to $56.3 million in 2000, reflecting ongoing investment in its pipeline. Regeneron's liquidity position remained strong, with $154.4 million in cash, cash equivalents, and marketable securities as of December 31, 2000, and management anticipated sufficient funding through the third quarter of 2002.

Key Highlights

  • 1Regeneron has a robust pipeline with multiple product candidates in various stages of development, including AXOKINE for obesity, IL-1 TRAP for rheumatoid arthritis, and VEGF TRAP for cancer.
  • 2The company reported a net loss of $23.2 million for the year ended December 31, 2000, with total revenues growing to $59.3 million, primarily from collaboration and contract manufacturing.
  • 3AXOKINE showed promising results in a Phase II obesity trial, demonstrating statistically significant weight loss and generally good tolerability, with Phase III trials planned for mid-2001.
  • 4Regeneron has established significant collaborations with major companies like Procter & Gamble and Amgen, which provide funding and support for its research and development efforts.
  • 5The company possesses proprietary technology platforms, including Targeted Genomics(TM), High Throughput Functionomics(TM), and Designer Protein Therapeutics(TM), which are crucial for its drug discovery and development capabilities.
  • 6Despite ongoing losses, Regeneron maintains a strong cash position with $154.4 million in cash, cash equivalents, and marketable securities as of year-end 2000, projecting sufficient funding into mid-2002.
  • 7The company faces substantial competition in the biopharmaceutical industry, and the success of its product candidates is subject to regulatory approvals, clinical trial outcomes, and market acceptance.

Frequently Asked Questions

Regeneron's core strategy is to combine strong scientific and technological foundations with state-of-the-art manufacturing and clinical development capabilities to build an integrated biopharmaceutical company. A key aspect is retaining significant ownership and commercialization rights to its product pipeline, which aims to address serious unmet medical needs.

Regeneron's leading product candidates include AXOKINE (for obesity), IL-1 TRAP (for rheumatoid arthritis and inflammatory diseases), IL-4/IL-13 TRAP (for asthma and allergic disorders), and VEGF TRAP (for cancer and related conditions). Pegylated AXOKINE is a modified version of AXOKINE aimed at longer action.

For the year ended December 31, 2000, Regeneron reported a net loss of $23.2 million on revenues of $59.3 million. While revenues increased significantly from the prior year, driven by collaborations and contract manufacturing, the company continued to invest heavily in research and development, leading to operational losses.

Regeneron has historically financed its operations through private and public equity offerings, revenue from collaboration agreements (notably with Procter & Gamble and Amgen), contract manufacturing income (with Merck), and investment income. As of December 31, 2000, the company held $154.4 million in cash and marketable securities, which management believed was sufficient to fund operations through the third quarter of 2002.